Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Acetylation reprograms MITF target selectivity and residence time
28 September 2023
A role for ASPP2 in Hepatitis C infection
28 September 2023
Vacancies: Assistant and/or Associate Professor Level Cancer Researchers
21 September 2023
Ludwig Oxford Professor Announced
12 September 2023
Publications
-
Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?
Journal article
Havelange V. and Constantinescu SN., (2023), American journal of hematology, 98, 1512 - 1516
-
Acetylation reprograms MITF target selectivity and residence time
Journal article
Louphrasitthiphol P. et al, (2023), Nature Communications, 14
-
ASPP2 binds to hepatitis C virus NS5A protein via an SH3 domain/PxxP motif-mediated interaction and potentiates infection
Journal article
Smirnov A. et al, (2023), Journal of General Virology, 104
Seminars
